维得利珠单抗治疗UC疗效、安全性良好,更具经济学优势,成为UC患者较好的选择。结语 维得利珠单抗用于UC患者治疗应答获益高,早期即可显著改善症状,长期临床缓解率、黏膜愈合率高,同时安全性良好,有效降低UC疾病负担。除此之外,与TNF-α抑制剂相比,维得利珠单抗更具经济学优势。 目前,全世界范围内已有50多个国家和地区将维得利珠单抗纳入医保。未来期待维得利珠单抗也能够早日进入中国国家医保目录,成为UC患者更具性价比的治疗选择,造福更多UC患者。 参考文献: [1]Ng SC, Kaplan GG, Tang W, et al. Am J Gastroenterol. 2019 Jan;114(1):107-115 [2]Solberg IC, Lygren I, Jahnsen J, et al. Scand J Gastroenterol. 2009;44(4):431-40 [3]Rutter M, Saunders B, Wilkinson K, et al. Gastroenterology. 2004 Feb;126(2):451-9. [4] Fumery M, et al. Clin Gastroenterol Hepatol. 2018;16(3):343-356. [5] 赵媛媛, 顾洁, 张媛媛,等. 中华现代护理杂志, 2018, 24(16):1895-1899. [6] Rui Liu, et al. 2018; 24(9): 2039-2047. [7] Lichtenstein GR, Shahabi A, Seabury SA, et al. Clin Gastroenterol Hepatol. 2020;18(4):889-897.e10. 2. [8] Xu J, Tang M, Shen J. Gastroenterol Res Pract. 2013;2013:267630. [9] 周青杨, 钱家鸣. 中华消化杂志,2020,40 (02): 141-144. [10] Ulf Helwig, Michael Mross, Stefan Schubert,et al. BMC Gastroenterology ,2020,20(211),1-15. [11] Lichtenstein L, Ron Y, Kivity S, et al. J. Crohns. Colitis 2015, 9, 806–15. [12] Melo FJ, Magina S, et al. Int J Dermatol. 2018 Dec;57(12):1521-1532. [13] Brijs K, Miclotte I, Vermeire S, et al. Int J Oral Maxillofac Surg. 2020 Mar;49(3):317-324. [14] Beaugerie L, Kirchgesner J. Clinical Gastroenterology and Hepatology. 2019; 17(3): 370-379. [15] Colombel, Jean-Frédéric, Sands B E , Rutgeerts P , et al. Gut, 2017, 66(5):839-851. [16] Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al.; N Engl J Med. 2019 Sep 26;381(13):1215-1226. [17] Edward V. Loftus Jr, Brian G. Feagan,Remo Panaccione.Aliment Pharmacol Ther. 2020;00:1–13. [18] 中国药物经济学评价指南2019. [19] Hernandez L,et al. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. Pharmacoeconomics. 2020 Jan;38(1):69-84. [20] Sheng Y, et al. Cost-Effectiveness Comparison of Vedolizumab, Infliximab and Conventional Therapy for the Treatment of Biologic-Naïve, Moderately to Severely ACTIVE Ulcerative Colitis Patients in China. ISPOR Europe 2020. |
|